Organized for easy navigation American Diagnostica Inc (ADI) announces the release of a new full-color product catalog. The catalog highlights and clearly describes the entire line of ADI products available to the clinical diagnostic, hemostasis, oncology, vascular biology, drug-discovery, and life science markets, while illustrating a wide selection of industry-respected and acknowledged test kits, assays, research reagents, control materials, and calibrators/standards. The catalog is broken down into nine sections with expanded descriptions, emphasizing recently introduced products and those that are FDA cleared and/or CE marked. Products are easy to locate and are arranged alphabetically by category, as follows: clinical diagnostic assays, research assays, control plasma and sera, proteins, antibodies and antisera (including clone, host, and application information), chromogenic and fluorogenic substrates, protease inhibitors, snake venom protease activators, and special collection tubes for blood. Also included are two product-specific indexes arranged alphabetically and numerically by product reference number and a worldwide listing of distributors. The product catalog is designed for medical laboratory professionals and drug-discovery scientists.
Treatment-Identification Test For molecularly targeted anti-cancer therapies A new laboratory test by the Weisenthal Cancer Group accurately identifies patients who would benefit from treatment with the molecularly-targeted anticancer therapies gefitinib (Iressaâ, AstraZeneca) and erlotinib (Tarcevaâ, Genentech). The new test, the EGFRxä assay, predicted accurately for the survival of patients treated with the targeted drugs. The finding is important because the EGFRxä test, which can also be applied to many emerging targeted cancer drugs, could help solve the growing problem of knowing which patients should receive costly, new treatments that can have harmful side effects and which work for some but not all cancer patients who receive them. Larry Weisenthal, MD, PhD, a medical oncologist and developer of the EGFRxä assay, explains that the new test relies upon what he calls “Whole Cell Profiling,” in which living tumor cells are removed from an individual cancer patient and exposed in the laboratory to the new drugs. A variety of metabolic and apoptotic measurements are then used to determine if a specific drug was successful at killing the patient’s cancer cells. The whole cell-profiling method differs from other tests in that it assesses the activity of a drug upon combined effect of all cellular processes, using several metabolic and morphologic end points. Other tests, such as those that identify DNA or RNA sequences or the expression of individual proteins, often examine only one component of a much larger, interactive process.
Laser Microdissection System Equipped with up to 150x magnification The newest laser microdissection system from Leica Microsystems can be used for cancer research, other areas of pathology, proteomics, genomics, gene-expression profiling, or neuroscience. The Leica LMD6000 is characterized by intelligent automation, improved performance, optimized specimen throughput, and high precision, with innovations in all areas of obtaining materials for analysis. With its enhanced laser technology, the Leica LMD6000 is suitable for processing thicker specimens and harder materials. With improved optics and exact laser control, the Leica LMD6000 enables high-precision, high-velocity collection of very small objects, such as individual cells. Owing to optical laser control, stage movements do not influence the quality of the results. Even chromosomes can be easily cut—the LMD6000 is equipped with up to 150x magnification.
The nation's leading provider of diagnostic medical imaging services with 25 years of industry experience is seeking qualified professionals to join their team.
Laser Microdissection System 
Experts here are available to answer all your questions!
